News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Markets were broadly muted in the past hour with no major headlines to drive volatility.
  • US equities showed little movement and trading volumes stayed light amid headline absence.
  • Treasury yields and major currencies traded in narrow ranges without fresh economic data or central bank comments.
  • Oil and commodity prices saw minimal change as no supply shocks or demand news emerged.
  • No significant geopolitical or political developments were reported in the last hour.
  • Investors stayed in wait-and-see mode ahead of scheduled economic releases and earnings later today.

Latest Articles

Tesla Considers China Exit as Pathway to a Potential SpaceX Combination

Tesla Considers China Exit as Pathway to a Potential SpaceX Combination

Reports that Tesla is internally evaluating a spinoff, sale, or closure of its China operations have intensified speculation that a merger with SpaceX could be proceeding. Elon Musk declined to rule out a combination on Tesla’s July 22 earnings call, and market reactions and analyst probability estimates have shifted accordingly. SpaceX shares have…

Six Stocks That Fit a True 'Set-and-Forget' Playbook for Long-Term Holders

Six Stocks That Fit a True 'Set-and-Forget' Playbook for Long-Term Holders

A rules-based screener targeting sustained top-line growth, strong returns on capital, healthy balance sheets and meaningful five-year price appreciation returned 68 U.S. names. Six companies emerge as archetypal long-term compounders: NVIDIA, Broadcom, Meta Platforms, Eli Lilly, Arista Networks and Fortinet. Each combines durable economics with sc…

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis, Inc., a medical technology firm focused on cardiorenal solutions, announced it entered into a securities purchase agreement to sell approximately 1.31 million shares of common stock at $2.59 per share in an at-the-market registered direct offering under Nasdaq rules, raising $3.4 million. Concurrently, the company received $3.1 million fr…

Twist in U.S. Treasury Curve Signals Market Doubts About Further Fed Hikes

Twist in U.S. Treasury Curve Signals Market Doubts About Further Fed Hikes

After the Federal Reserve left interest rates unchanged, U.S. Treasury yields moved in opposite directions: short-dated yields fell while longer-dated notes climbed, particularly at the 30-year end. The resulting steepening - described by some strategists as a 'twist steepener' - has been read by market participants as reduced odds of further Fed h…

Fed Split Widens as Three Presidents Push for Immediate Rate Rise

Fed Split Widens as Three Presidents Push for Immediate Rate Rise

At the July 28-29 FOMC meeting the Federal Reserve held the federal funds rate at 3.50%-3.75% in a 9-3 vote, marking a fifth straight pause. Minneapolis Fed President Neel Kashkari, Cleveland Fed President Beth Hammack, and Dallas Fed President Lorie Logan dissented, each voting for an immediate 0.25 percentage point increase, warning that continue…

BCA Research: Opportunity Emerging for Gold as Near-Term Headwinds Ease

BCA Research: Opportunity Emerging for Gold as Near-Term Headwinds Ease

BCA Research told clients that gold's recent decline is showing signs of exhaustion and that the tactical obstacles to higher prices are diminishing. The firm highlights real interest rates and the U.S. dollar as the primary drivers of gold, says central bank buying now offers a price floor, and recommends a long position as the worst of the pullba…

Netcapital Provides Update on SEC Stay

Netcapital Provides Update on SEC Stay

Netcapital Inc. reports that the SEC has stayed the recently approved Nasdaq rule requiring companies with market value of listed securities (MVLS) below $5 million to face immediate delisting. The full SEC Commission will review the rule, currently suspended, providing Netcapital and other small-cap Nasdaq companies more time to focus on turnaroun…

Nasdaq Resumes Trading in Jiade Limited

Nasdaq Resumes Trading in Jiade Limited

Trading in Jiade Limited's Class A Ordinary Shares, which had been halted on June 4, 2026, resumed on July 31, 2026 at 12:00 p.m. Eastern Time on the Nasdaq stock exchange. The announcement comes directly from Nasdaq with no specific reasons or additional details provided about the resumption or prior trading halt.

Shaboozey’s “Outlaw” Is Wanted in Every Record Store in America

Shaboozey’s “Outlaw” Is Wanted in Every Record Store in America

Alliance Entertainment Holding Corporation, via its AMPED Distribution division, is orchestrating a comprehensive nationwide retail marketing campaign for Shaboozey’s new album 'The Outlaw Cherie Lee & Other Western Tales.' The campaign integrates independent record stores, major retailers, and e-commerce platforms, featuring listening parties, exc…

Cerenome Launches as an Integrated CNS Oncology Company

Cerenome Launches as an Integrated CNS Oncology Company

Plus Therapeutics, Inc. is rebranding as Cerenome, Inc., with a new Nasdaq ticker CNSY, reflecting its transformation into an integrated central nervous system (CNS) oncology company. Cerenome aims to combine precision diagnostics (CNSide®), targeted radiotherapeutics (REYOBIQ™), and proprietary data analytics powered by artificial intelligence to …

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Therapeutics, a late clinical-stage biopharmaceutical company specializing in intranasal neurocircuitry-focused treatments, announced the appointment of Douglas J. Williamson, MD, to its Board of Directors. Dr. Williamson brings extensive experience in neuroscience drug development and regulatory approvals, expected to strengthen Vistagen'…